SOLV

Solventum

$88.65

-0.48%
Nov 16, 2026
Bobby Quantitative Model
Solventum Corporation is the healthcare business that 3M spun off as an independent public company in spring 2024, operating across three segments: MedSurg (roughly 64% of revenue, anchored by advanced wound care and wound prevention), Dental Solutions (restorative composites and orthodontia), and Health Information Systems (primarily revenue cycle management), with the smaller purification and filtration unit having been divested. As a newly standalone entity, Solventum is a scaled but non-platform medtech supplier with leading share in wound care and dental consumables, yet it lacks the pricing power and growth profile of higher-multiple surgical and device peers. The investor narrative is dominated by post-spin execution: deleveraging a balance sheet inherited from 3M, resolving stranded-cost dis-synergies, portfolio pruning (the purification sale and a roughly $676 million acquisition in Q4 2025), and a Q3 2026 revenue decline of 7.0% year over year that has revived debate over whether the company can stabilize organic growth. Recent analyst actions have skewed constructive—UBS upgraded to Buy in late July 2026 and multiple firms reiterated Overweight/Buy ratings after Q3 results—while the stock's 18.4% one-year gain suggests the market is rewarding cash generation and margin discipline even as the top line remains soft.

People also watch

Intuitive Surgical

Intuitive Surgical

ISRG

Analysis
Becton Dickinson

Becton Dickinson

BDX

Analysis
ResMed

ResMed

RMD

Analysis
Modernland Realty Ltd

Modernland Realty Ltd

MDLN

Analysis
West Pharmaceutical Services (United States)

West Pharmaceutical Services (United States)

WST

Analysis

BobbyInvestment Opinion: Should I buy SOLV Today?

Rating: Hold, with a constructive bias. The thesis is that SOLV is a cash-generative, deeply discounted post-spin medtech franchise whose ~8.0x forward multiple on consensus EPS of $11.18 already discounts continued revenue erosion, but a 7.01% Q3 2026 revenue decline and a -$12 million GAAP loss mean the recovery is not yet proven. The six-analyst consensus is Buy-skewed (Piper Sandler Overweight, BTIG Buy, KeyBanc Overweight, UBS Buy, Stifel Buy, Wedbush Outperform, Wells Fargo Equal Weight, no Sells), but no average price target was disclosed, so the rating rests on valuation and earnings conviction rather than a quantified upside figure.

The supporting evidence is valuation-led: at $89.08 the stock trades at ~8.0x the $11.18 consensus EPS and 7.04x EV/EBITDA versus the high-teens-to-low-20s forward multiple typical of medical instruments, a roughly 55-60% discount, while P/S of 1.66x sits well below the sector's 3-4x range. Gross margin has held in a tight 54.5%-58.2% band over four quarters (54.49% in Q3 2026), and Q3 2026 generated $179 million of operating cash flow and $99 million of free cash flow after $80 million of capex, funding $48 million of buybacks. The tight $11.05-$11.32 EPS estimate band (a 2.4% spread) and $9.54-$9.72 billion revenue band (1.8% spread) show analysts broadly agree on near-term earnings power despite the soft top line.

The risks that could invalidate the thesis are a failure of MedSurg wound care (roughly 64% of the $1.884 billion three-segment total) to stabilize, leverage of 0.997 debt-to-equity with a 1.23 current ratio limiting buyback and M&A flexibility, and interest expense of $68 million per quarter keeping GAAP earnings negative. This Hold would upgrade to Buy if Q4 revenue decline narrows toward flat and operating margin recovers above the 8.19% seen in Q2 2026, or if the stock pulls back toward the $81-$82 support zone; it would downgrade to Sell if revenue declines accelerate beyond -7% or free cash flow turns negative again as it did in Q1 2026 (-$273 million). On balance the stock looks undervalued relative to its own post-spin P/S band and to peers, but fairly valued for a shrinking, levered business until organic growth inflects.

Sign up to view all

SOLV 12-Month Price Forecast

SOLV presents a valuation-versus-execution trade: the ~8.0x forward multiple, 7.04x EV/EBITDA, and 1.66x P/S embed a 55-60% discount to medtech peers that is only justified while revenue shrinks and leverage stays near 1.0x debt-to-equity. The operating business is healthier than the headline -$12 million net loss suggests, with gross margin holding near 54.5% and Q3 free cash flow of $99 million, but the 7.01% revenue decline and $68 million quarterly interest burden keep the equity case unproven. Analyst sentiment is constructive with six Buy-skewed ratings and a tight $11.05-$11.32 EPS band, yet the absence of a disclosed average target limits conviction on upside. I would upgrade to bullish if Q4 shows revenue decline narrowing toward flat with operating margin back above 8%, and downgrade to bearish if revenue declines accelerate or free cash flow turns negative again. With 55% probability on the base case and the stock already near the top of its 52-week range, the risk/reward is balanced rather than compelling.

Historical Price
Current Price $88.65
Average Target $88.65
High Target $101.95
Low Target $75.35

Wall Street consensus

Six analysts cover SOLV, and the sentiment is decidedly constructive: the institutional ratings log shows a preponderance of Buy-equivalent calls—Piper Sandler Overweight (reiterated November 6, 2026), Wells Fargo Equal Weight (reiterated same day), BTIG Buy, KeyBanc Overweight, UBS Buy (upgraded from Neutral on July 28, 2026), Stifel Buy, and Wedbush Outperform—with only Wells Fargo sitting at Equal Weight and no Sell ratings in the record. The consensus leans bullish, with the UBS upgrade the most notable recent positive catalyst, and the consensus EPS estimate of $11.18 (range $11.05-$11.32) implies the Street expects earnings to hold up despite the revenue decline. A specific average price target was not provided in the data, so implied upside cannot be calculated precisely; however, the tight EPS estimate range (a spread of only about 2.4%) signals high conviction in near-term earnings power.\n\nThe target range and estimate dispersion tell a story of moderate rather than extreme uncertainty: the $11.05 low to $11.32 high EPS band is narrow, implying analysts broadly agree on the earnings trajectory, while the revenue estimate range of $9.54 billion to $9.72 billion (a spread of about 1.8%) suggests limited disagreement on the top line as well. The bullish case assumes margin recovery as spin-related stranded costs roll off, debt reduction from free cash flow, and stabilization in MedSurg wound care—potentially with multiple expansion from the current ~8x forward PE toward low-double-digits. The bear case (represented by Wells Fargo's Equal Weight) likely prices in continued revenue erosion, elevated leverage limiting buybacks and M&A, and the risk that Q3's GAAP loss becomes a recurring pattern if interest costs stay high. With six covering analysts and a mix of reiterations rather than fresh initiations, coverage is adequate but not deep—typical for a recent spin-off—which can amplify volatility around earnings and means price discovery is less efficient than for a large-cap medtech peer with 20+ analysts.

Drowning in data?

Find the real signal!

Bulls vs Bears: SOLV Investment Factors

The bear case currently has the stronger hard evidence: revenue fell 7.01% year over year in Q3 2026, GAAP net income turned negative at -$12 million, and trailing free cash flow is a negligible $2 million against a 0.997 debt-to-equity ratio. The bull case rests on valuation and expectations rather than realized results—an ~8x forward PE, 7.04x EV/EBITDA, and a 54.5% gross margin imply the operating business is healthier than the headline loss suggests, and six analysts with a tight $11.05-$11.32 EPS band are betting on margin recovery as stranded costs roll off. The single most important tension is whether MedSurg wound care stabilizes: if organic revenue inflects, the leverage-and-execution discount can compress toward peer multiples and the stock re-rates sharply; if the decline persists, the ~8x multiple is a fair price for a shrinking, levered business rather than a bargain. Momentum and relative strength (+17.83 points versus SPY over six months) show the market is already leaning toward the recovery view, which raises the bar for Q4 execution.

Bullish

  • Deep discount to medtech peers: At $89.08 the stock trades at roughly 8.0x the consensus EPS of $11.18 (trailing PE 8.86x) and 7.04x EV/EBITDA, versus the medical instruments industry's typical high-teens to low-20s forward multiple. That is a 55-60% earnings-multiple discount and a 1.66x P/S versus a sector norm of 3-4x, pricing in substantial pessimism for a franchise with leading wound-care share.
  • Gross margin holds near 55%: Gross margin has stayed in a tight 54.5%-58.2% band over the past four quarters, including 54.49% in Q3 2026 despite a 7.0% revenue decline. That stability shows the core consumables economics remain intact and that the earnings problem sits below the gross line (interest and stranded costs), which is fixable.
  • Analyst consensus firmly constructive: Six covering analysts skew Buy-equivalent—Piper Sandler Overweight, BTIG Buy, KeyBanc Overweight, UBS Buy (upgraded from Neutral July 28, 2026), Stifel Buy, Wedbush Outperform—with only Wells Fargo at Equal Weight and no Sell ratings. The $11.05-$11.32 EPS estimate band (a 2.4% spread) signals high conviction that earnings hold up despite soft revenue.
  • Cash generation and deleveraging path: Q3 2026 produced $179 million of operating cash flow and $99 million of free cash flow after $80 million of capex, and the company retired $48 million of stock in Q3 and $288 million in Q2. Consistent FCF against a 0.997 debt-to-equity ratio is the mechanism by which the leverage penalty on the multiple can unwind.

Bearish

  • Revenue shrinking 7% year over year: Q3 2026 revenue of $1.949 billion fell 7.01% from $2.096 billion a year earlier and declined sequentially from $2.207 billion in Q2 2026. Consensus forward revenue of $9.62 billion implies flat-to-down sales, so the top line—not margins—is the unresolved problem.
  • GAAP loss as interest swamps operations: Q3 2026 net income was -$12 million (EPS -$0.07) as $68 million of interest expense plus $79 million of net other expenses overwhelmed $68 million of operating income (3.49% operating margin). Operating margin compressed from 8.19% in Q2 to 3.49% in Q3, showing how thin the equity cushion is at the operating line.
  • Leverage and negligible trailing FCF: Debt-to-equity of 0.997 and a current ratio of just 1.23 leave limited flexibility, and trailing free cash flow is only $2 million (PCF 37.4x) after Q1 2026 burned $189 million of operating cash flow. Buybacks and the ~$676 million Q4 2025 acquisition compete directly with debt paydown for the same cash.
  • MedSurg concentration drives the trend: MedSurg at $1.211 billion is roughly 64% of the $1.884 billion three-segment total, with Health Information Systems at $356 million and Dental at $317 million—neither large enough to offset a MedSurg slowdown. The consolidated growth story is effectively a single-franchise bet on wound care stabilization.

SOLV Technical Analysis

SOLV is in a sustained, stair-step uptrend: the stock has gained 18.43% over the past year and 12.73% year to date, and at $89.08 it sits essentially at the top of its 52-week range, roughly 100% of the way from the low to the high (the 52-week high of $92.44 was set on September 3, 2026, and the low is implied near $75 by the May 2026 trading around $73.56-$76.83). Trading at the upper bound of the range signals momentum leadership rather than overextension, particularly since the advance has been orderly—the maximum drawdown over the period was a contained -27.46%—and the stock has repeatedly consolidated rather than spiking. This positioning means buyers have been rewarded on dips, but it also leaves little valuation cushion if momentum stalls near resistance.\n\nShort-term momentum is positive but decelerating relative to the longer trend: the stock is up 2.09% over the past month and just 0.55% over three months, versus 19.96% over six months and 18.43% over a year, a clear flattening of the rate of change after the powerful July-August run from $78.01 on July 24 to $91.61 on August 25. The one-month gain also masks a sharp October pullback to $81.33 on October 30 followed by a V-shaped recovery to $89.08 by November 13, a swing that suggests dip-buying support rather than distribution. Importantly, relative strength remains decisively positive across every window—+4.35 points versus SPY over one month, +3.38 over three months, and +17.83 over six months—even as SPY itself fell 2.26% and 2.83% over the one- and three-month periods, meaning SOLV's modest absolute gains are actually strong outperformance. Volume data was not available (reported as zero), so momentum confirmation must rest on price structure alone.\n\nKey technical levels are well defined: resistance sits at the $92.44 September high, with a breakout above that level opening the door to fresh all-time-high territory and likely triggering momentum-fund accumulation, while support rests in the $81-$82 zone (the late-October low of $81.33 and the August 6 close of $82.96), with deeper support at the May 2026 base near $73.56. A breakdown below $81 would break the pattern of higher lows that has held since June and would put the 52-week low area back in play. Beta is not available in the provided data, but the -27.46% maximum drawdown and the roughly $11 intraday-range swings between the September high and October low imply above-market volatility for a large-cap medtech name, which argues for smaller position sizing and wider stops than a typical defensive healthcare holding would require.

Beta

—

—

Max Drawdown

-27.5%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

+17.2%

Cumulative gain past year

PeriodSOLV ReturnS&P 500
1m+3.3%-3.0%
3m+1.4%-3.6%
6m+16.4%-0.2%
1y+17.2%+10.1%
ytd+12.2%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

SOLV Fundamental Analysis

The revenue trajectory is the central fundamental concern: Q3 2026 revenue of $1.949 billion fell 7.01% year over year from $2.096 billion in Q3 2025, extending a pattern of sequential erosion from $2.207 billion in Q2 2026 and $2.007 billion in Q1 2026, with the prior-year quarters ranging from $1.998 billion to $2.161 billion. Segment data for the latest period shows MedSurg at $1.211 billion (roughly 64% of the $1.884 billion three-segment total), Health Information Systems at $356 million, and Dental Solutions at $317 million, confirming that the wound-care-heavy MedSurg franchise drives the consolidated trend and that no smaller segment is large enough to offset a MedSurg slowdown. The decline likely reflects a mix of divestiture effects (the purification and filtration sale), currency, and soft underlying demand, but the investment case now hinges on stabilization—consensus estimates of $9.62 billion in forward revenue imply roughly flat-to-modestly-down full-year sales versus the 2025 run-rate, so any return to organic growth would be a meaningful positive catalyst.\n\nProfitability is thin and volatile at the GAAP line but solid at the operating level: Q3 2026 net income was -$12 million (EPS -$0.07) on a 54.49% gross margin, a sharp reversal from Q2 2026's $92 million profit (4.16% net margin, 58.22% gross margin) and Q1 2026's $13 million (0.65% net margin, 54.66% gross margin). The Q3 loss was driven by $68 million of interest expense and $79 million of net other expenses against only $68 million of operating income (3.49% operating margin), highlighting how a leveraged post-spin capital structure can wipe out equity earnings even at healthy gross margins. Gross margin has held in a tight 54.5%-58.2% band over the past four quarters, which is respectable for a consumables-heavy medtech mix, but operating margin has compressed from 8.19% in Q2 to 3.49% in Q3, and the trailing twelve-month net margin of 18.69% is flattered by a one-time $1.377 billion gain in Q3 2025 that is not repeatable. The key question is whether management can push operating margin back toward the high-single digits as spin-related stranded costs roll off.\n\nThe balance sheet is the swing factor: debt-to-equity stands at 0.997, the current ratio is 1.23, and cash flow is uneven—Q3 2026 operating cash flow was $179 million with $99 million of free cash flow after $80 million of capex, but Q1 2026 burned $189 million of operating cash flow (FCF of -$273 million) on working capital, leaving trailing free cash flow at just $2 million and a PCF ratio of 37.4x. Cash on hand was $451 million at quarter-end against meaningful debt service ($68 million quarterly interest), and the company repurchased $48 million of stock in Q3 and $288 million in Q2, signaling confidence but also competing with deleveraging for capital. ROE of 30.8% looks strong but is distorted by the one-time gain and a 2.95x equity multiplier; on a clean basis, return on capital employed was just 0.64% in Q3 2026, underscoring that the company is not yet earning its cost of capital and remains dependent on internal cash generation improving before the leverage overhang can be retired.

Quarterly Revenue

$1.9B

2026-09

Revenue YoY Growth

-7.0%

YoY Comparison

Gross Margin

54.5%

Latest Quarter

Free Cash Flow

$2000000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Dental Solutions Segment
Health Information Systems Segment
MedSurg Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is SOLV Overvalued?

Because trailing net income is positive but heavily distorted by one-time items (the Q3 2025 gain and the Q3 2026 loss), the trailing PE of 8.86x is not a reliable anchor; the more meaningful lens is the forward PE of roughly 0.04x implied by the provided forward figure, which is clearly a data artifact, so the cleanest read comes from the analyst consensus EPS of $11.18 against the $89.08 price—an implied forward multiple of about 8.0x, versus a trailing PE of 8.86x. The near-identical trailing and forward multiples imply the market is pricing in essentially no earnings growth, consistent with the -7.0% revenue decline and flat consensus revenue of $9.62 billion. On EV/EBITDA of 7.04x and P/S of 1.66x, the stock screens as a low-multiple, cash-flow-oriented medtech value name rather than a growth compounder.\n\nAgainst the broader medical instruments and supplies industry, which typically trades in the high-teens to low-20s on forward earnings, SOLV's ~8x forward PE represents a discount of roughly 55-60%, and its 1.66x P/S is well below the sector's typical 3-4x range. That discount is partly justified: revenue is shrinking, GAAP earnings are volatile, leverage (D/E ~1.0) is elevated for a spin-off, and trailing free cash flow of just $2 million is negligible against a $13.8 billion market cap. However, the 53.47% gross margin and 26.20% operating margin (the latter flattered by the one-time gain) suggest the underlying business economics are better than the headline multiple implies, and the 7.04x EV/EBITDA is cheap for a franchise with leading wound-care share—so the discount looks more like a leverage-and-execution penalty than a structural value trap.\n\nHistorically, SOLV's own valuation band has been wide and noisy since its 2024 listing: quarterly PE ratios in the historical data range from 2.51x (Q3 2025, distorted by the gain) to 233.2x (Q1 2026, distorted by near-zero earnings), with P/S ranging from 4.28x (Q2 2024) to 7.72x (Q3 2026) and P/B from 1.18x (Q4 2023) to 4.05x (Q1 2025). At a current P/B of 2.73x and P/S of 1.66x, the stock sits in the lower half of its post-spin P/B range and at the low end of its P/S band, suggesting the market is not pricing in optimistic expectations—rather, it is discounting continued revenue erosion and slow deleveraging. If management delivers margin recovery and debt paydown, re-rating toward the mid-point of its historical P/S range (roughly 5-6x) would imply substantial upside; failure to stabilize the top line would keep the stock anchored near these depressed multiples.

PE

8.9x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 3x~55x

vs. Industry Avg

40.3x

Industry PE ~40.3x*

EV/EBITDA

7.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on a leveraged post-spin balance sheet colliding with a shrinking top line. Q3 2026 revenue of $1.949 billion fell 7.01% year over year, and $68 million of quarterly interest expense plus $79 million of net other expenses turned $68 million of operating income into a -$12 million net loss, a 3.49% operating margin versus 8.19% in Q2. Trailing free cash flow is just $2 million (PCF 37.4x) after Q1 2026 burned $189 million of operating cash flow, and with debt-to-equity at 0.997 and a current ratio of 1.23, the company has limited room to absorb a working-capital shock. Concentration compounds this: MedSurg is roughly 64% of the $1.884 billion three-segment total, so a continued wound-care slowdown cannot be offset by Health Information Systems ($356 million) or Dental ($317 million).

Market and competitive risks stem from a valuation that is cheap for a reason and a franchise without pricing power. At ~8.0x consensus EPS of $11.18 and 7.04x EV/EBITDA, SOLV trades at a 55-60% discount to the high-teens-to-low-20s forward multiple typical of medical instruments, and its 1.66x P/S sits below the sector's 3-4x range—a discount that persists only as long as revenue erodes and leverage stays elevated. The wound-care and dental-consumables categories are mature and price-sensitive, leaving little cushion if a competitor or payer pressure hits MedSurg. Coverage is thin at six analysts, and the stock's -27.46% maximum drawdown plus the $11 swing between the September 3 high of $92.44 and the October 30 low of $81.33 imply above-market volatility for a large-cap medtech name, magnifying sector-rotation damage.

The worst-case scenario is a self-reinforcing loop: MedSurg fails to stabilize, Q4 revenue declines again, stranded costs prove stickier than guided, and interest expense keeps GAAP earnings negative, forcing management to choose between buybacks and deleveraging while analysts cut estimates. In that path the stock would retest the 52-week low area near $73.56 (the June 22, 2026 close), roughly -17% from $89.08, and a break below the $81-$82 support zone would confirm the pattern of higher lows has failed. A more severe outcome—multiple compression back toward the low end of its post-spin P/S band alongside an earnings miss—could push toward the mid-$70s or below, a -20% to -25% drawdown from current levels and consistent with the -27.46% max drawdown already experienced.

FAQ

The most severe risk is financial: leverage of 0.997 debt-to-equity and a 1.23 current ratio combine with $68 million of quarterly interest expense to turn $68 million of Q3 2026 operating income into a -$12 million net loss, leaving little cushion if cash flow disappoints. Second is operational concentration—MedSurg at $1.211 billion is roughly 64% of the $1.884 billion three-segment total, so a continued wound-care decline cannot be offset by Health Information Systems ($356 million) or Dental ($317 million), and consolidated revenue already fell 7.01% year over year. Third is cash-flow volatility: trailing free cash flow is just $2 million after Q1 2026 burned $189 million of operating cash flow, meaning a repeat working-capital swing would force a choice between buybacks and deleveraging. Fourth is market-structure risk—only six analysts cover the name, and the stock swung from $92.44 on September 3 to $81.33 on October 30 before recovering to $89.08, with a -27.46% maximum drawdown, so earnings events can move the shares sharply. Ranked by severity: financial leverage first, MedSurg concentration second, cash-flow volatility third, thin coverage fourth.

The 12-month outlook splits into three scenarios. The base case carries 55% probability with a target range of $88-$100: revenue declines modestly, gross margin holds near 54%-55%, free cash flow stays positive, and the stock consolidates around its current ~8x forward multiple on $11.18 consensus EPS. The bull case at 25% probability targets $105-$115, requiring MedSurg stabilization, stranded spin costs rolling off, operating margin recovering above the 8.19% Q2 2026 level, and multiple expansion toward the low-double-digits. The bear case at 20% probability targets $73-$82, driven by a further revenue decline, recurring GAAP losses, and a retest of the $73.56 52-week low. The base case is most likely because the $11.05-$11.32 EPS estimate band (a 2.4% spread) shows analysts broadly agree earnings will hold despite the soft top line, and the stock already sits near the top of its 52-week range at $89.08, limiting near-term upside without a growth inflection.

On most measures SOLV screens as undervalued relative to peers but fairly valued for a shrinking, levered business. The trailing PE of 8.86x and implied forward multiple of about 8.0x on the $11.18 consensus EPS compare with high-teens to low-20s for medical instruments, and P/S of 1.66x sits well below the sector's 3-4x range, while EV/EBITDA of 7.04x is cheap for a franchise with leading wound-care share. Against its own post-spin history the stock is also near the low end: P/B of 2.73x is in the lower half of its historical range and P/S of 1.66x is far below the 4.28x-7.72x band seen since 2024. The market is clearly not paying a premium—it is discounting continued revenue erosion, a 0.997 debt-to-equity ratio, and GAAP losses driven by $68 million of quarterly interest. The implied expectation is essentially no earnings growth, so any evidence of MedSurg stabilization or margin recovery above the 8.19% Q2 level would likely trigger multiple expansion; conversely, a further revenue decline would confirm the discount as deserved.

The risk/reward is balanced rather than compelling at $89.08, which is why the synthesized view is Hold with a constructive bias. On the positive side, the stock trades at roughly 8.0x the $11.18 consensus EPS and 7.04x EV/EBITDA—a 55-60% discount to medical instruments peers—while gross margin holds at 54.49% and Q3 2026 free cash flow was $99 million, and six analysts skew Buy with no Sell ratings. On the negative side, revenue fell 7.01% year over year to $1.949 billion, GAAP net income was -$12 million as $68 million of interest expense swamped $68 million of operating income, and trailing free cash flow is only $2 million. The biggest downside risk is a retest of the $73.56 52-week low, roughly -17% from here, if MedSurg wound care (about 64% of the three-segment total) fails to stabilize. It is a reasonable buy for value-oriented investors with a 12-18 month horizon who can tolerate post-spin volatility, particularly on a pullback toward the $81-$82 support zone; it is less suitable for growth or income seekers given the 0% dividend and shrinking top line.

SOLV fits a medium-to-long-term holding period of at least 12-18 months better than short-term trading. The thesis depends on slow-moving developments—deleveraging a 0.997 debt-to-equity balance sheet, rolling off stranded spin-related costs, and stabilizing MedSurg wound care—none of which resolve in a single quarter, and the stock pays no dividend (0% yield, 0% payout ratio), so returns must come from price appreciation and multiple re-rating. Earnings visibility is moderate: the tight $11.05-$11.32 EPS band and $9.54-$9.72 billion revenue band show analysts agree on near-term numbers, but GAAP results are volatile (Q3 2026 EPS of -$0.07 versus $0.53 in Q2) because of interest and other expenses. Volatility is meaningful—the -27.46% maximum drawdown and the $11 swing between the September 3 high of $92.44 and the October 30 low of $81.33 argue against tight-stop short-term positioning. A patient investor buying near the $81-$82 support zone with a 12-18 month view is best positioned to capture a potential re-rating, while momentum traders should note the decelerating rate of change (+2.09% over one month versus +19.96% over six months).